Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by wofatson Jun 30, 2022 12:53pm
147 Views
Post# 34794223

RE:Big Pharma has compelling valuations & ‘ROOM to RUN’

RE:Big Pharma has compelling valuations & ‘ROOM to RUN’This big pharma may have to raise cash. 


Endo crashes 27% after missing interest payment

Endo International (NASDAQ:ENDPdropped ~27% in the pre-market Thursday after the generic drugmaker said it decided not to pay an interest payment of nearly $38M due on June 30 which relates to the company’s outstanding 6.00% Senior Notes due 2028. 

The nonpayment of interest is not considered an event of default, yet, Endo (ENDP) said, noting a 30-day grace period to make the payment according to terms of its Senior Notes. 

Endo (ENDP) has opted to enter the grace period as the company continues talks with certain creditors regarding its decision to evaluate strategic alternatives. 

Noting that the company had nearly $1.4N in cash as of March, the company said that the nonpayment of interest did not indicate liquidity issues and the decision would not have any impact in its day to day functions.

<< Previous
Bullboard Posts
Next >>